Q4 FY2025 · Presentation
ACMG 2026 ApproaCH Week 104 Data · 15 pages
Read Ascendis Pharma A/S's results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional
Ascendis Pharma A/S
257.93
USD
+7.76
(+3.10%)
Ascendis Pharma A/S Documents
Q4 FY2025 documents
Earnings release
5 pages
Feb 11, 2026
Annual report
Form 20-F · 300 pages
Feb 11, 2026
Presentation
2026 JPM Presentation - Final
30 pages
Presentation
ACMG 2026 ApproaCH Week 104 Data
15 pages
Presentation
Phase 2 COACH Trial Topline Week 52 Data
18 pages
Presentation
YUVIWEL® (navepegritide) FDA Approval
23 pages
Press release
5 pages
Mar 2, 2026
Press release
5 pages
Jan 8, 2026